Endothelial dysfunction enhances the pulmonary and systemic vasodilator effects of phosphodiesterase-5 inhibition in awake swine at rest and during treadmill exercise

Experimental Biology and Medicine

Volumn 237, Issue 2, 2012, Pages 201-210

  Houweling, Birgit ^a   Quispel, Johan ^a   Beier, Norbert ^b   Verdouw, Pieter D ^a   Duncker, Dirk J ^a   Merkus, Daphne ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MERCK KGAA   (Germany)

Author keywords

Endothelial dysfunction; Exercise; Phosphodiesterase 5; Pulmonary circulation

Indexed keywords

CYCLIC GMP; EMD 360527; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG; 8 BROMO CYCLIC GUANOSINE MONOPHOSPHATE; GUANOSINE PHOSPHATE; N (G) NITROARGININE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; SIGNAL TRANSDUCTION; SWINE; SYSTEMIC VASCULAR RESISTANCE; TREADMILL EXERCISE; VASODILATATION; ARTERIAL PRESSURE; BIOAVAILABILITY; BLOOD SAMPLING; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; INTRACELLULAR SIGNALING; LUNG CIRCULATION; MASS SPECTROMETRY; VASCULAR RESISTANCE;

ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; PHOSPHODIESTERASE 5 INHIBITORS; PHYSICAL CONDITIONING, ANIMAL; PULMONARY CIRCULATION; SWINE; VASCULAR RESISTANCE;

EID: 84857259413     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011232     Document Type: Article

References (52)

1. Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep 2008;60:119-26
2. Patel AR, Kuvin JT, Sliney KA, Rand WM, Pandian NG, Karas RH. Peripheral vascular endothelial function correlates with exercise capacity in women. Clin Cardiol 2005;28:433-6
3. Guazzi M. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 2008;1:272-80
4. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-403
5. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9
6. Patel MD, Katz SD. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. Am J Cardiol 2005;96:47M-51M
7. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-414
8. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005;334:930-8
9. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002;71:398-402
10. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM, Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gibbons RJ, Halperin JL, Hochman JS, Kaul S, Weintraub WS, Winters WL Jr, Wolk MJ. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99:168-77
11. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-96
12. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
13. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-22
14. Merkus D, de Beer VJ, Houweling B, Duncker DJ. Control of pulmonary vascular tone during exercise in health and pulmonary hypertension. Pharmacol Ther 2008;119:242-63
15. Reeves JT, Taylor AE. Pulmonary hemodynamics and fluid exchange in the lungs during exercise. In: Rowell LR, Shepherd JT, eds. Handbook of Physiology. Exercise: Regulation and Integration of Multiple Systems. Bethesda, MD: American Physiological Society, 1996:585-613
16. Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314-31
17. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115:59-66
18. Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 1985;110:807-13
19. 2-consumption in exercising swine. Cardiovasc Res 2000;47:738-48
20. Krumenacker JS, Hanafy KA, Murad F. Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull 2004;62:505-15
21. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65
22. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21
23. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80:1337-72
24. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH, Duncker DJ. Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res 2003;59:745-54
25. Stubenitsky R, Verdouw PD, Duncker DJ. Autonomic control of cardiovascular performance and whole body O2 delivery and utilization in swine during treadmill exercise. Cardiovasc Res 1998;39:459-74
26. Duncker DJ, Hartog JM, Levinsky L, Verdouw PD. Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig. Br J Pharmacol 1987;91:609-15
27. Zhang Q, Lazar M, Yan L, He Y, Tse J, Weiss HR, Scholz PM. Cyclic GMP reduces myocardial stunning through non-cyclic GMP protein kinase mechanisms. J Cardiovasc Pharmacol 2004;44:235-43
28. Matsumoto T, Kobayashi T, Kamata K. Phosphodiesterases in the vascular system. J Smooth Muscle Res 2003;39:67-86
29. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell Mol Physiol 1994;266:L536-43
30. Jeffery TK, Wanstall JC. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. J Cardiovasc Pharmacol 1998;32:213-9
31. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, Somers VK. Sympathetic activation by sildenafil. Circulation 2000;102:3068-73
32. Braner DA, Fineman JR, Chang R, Soifer SJ. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol Heart Circ Physiol 1993;264:H252-8
33. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, Zapol WM. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000;92:1702-12
34. Houweling B, Merkus D, Dekker MM, Duncker DJ. Nitric oxide blunts the endothelin-mediated pulmonary vasoconstriction in exercising swine. J Physiol 2005;568:629-38
35. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JSR. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 2005;171:1292-7
36. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62
37. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exerciseinduced vasodilatation in hypertensive patients. J Hypertens 2008;26:501-7
38. Tschakovsky ME, Joyner MJ. Nitric oxide and muscle blood flow in exercise. Appl Physiol Nutr Metab 2008;33:151-61
39. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharmacal Res 2009;32:1103-8
40. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009;157:527-36
41. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006;316:654-61
42. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 2008;326:380-7
43. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993;74:1704-11
44. Singel DJ, Stamler JS. Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Ann Rev Physiol 2005;67:99-145
45. Hartsfield CL. Cross talk between carbon monoxide and nitric oxide. Antioxid Redox Signal 2002;4:301-7
46. 2 mechanisms of guanylate cyclase activation in oxygen-dependent responses of rat pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 1995;268:L546-50
47. Botros FT, Navar LG. Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. Am J Physiol Heart Circ Physiol 2006;291:H2772-8
48. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006;129:417-25
49. Hussain MB, MacAllister RJ, Hobbs AJ. Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 2001;280:H1151-9
50. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:861-9
51. van Deel ED, Merkus D, van Haperen R, de Waard MC, de Crom R, Duncker DJ. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2007;293:H1144-53
52. Moncada S, Rees DD, Schulz R, Palmer RM. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 1991;88:2166-70